A sec­ond wave of check­point in­hibitors is swelling fast, with speedy BeiGene leap­ing in­to a piv­otal tri­al

Every­body wants their own check­point in­hibitor, or so it may seem.

Now that the bi­ol­o­gy is thor­ough­ly un­der­stood, we’re see­ing a sec­ond wave of late-stage pro­grams tak­ing shape — each with their own niche mar­kets in mind for dis­rup­tion.

To­day, you can add Bei­jing-based Beigene $BGNE to that list.

The biotech dosed their first pa­tient with re­frac­to­ry clas­si­cal Hodgkin lym­phoma — or cHL — with their an­ti-PD-1 drug BGB-A317 in a piv­otal study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.